<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02529930</url>
  </required_header>
  <id_info>
    <org_study_id>VB C-01</org_study_id>
    <nct_id>NCT02529930</nct_id>
  </id_info>
  <brief_title>An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3)</brief_title>
  <official_title>An Exploratory Safety and Immunogenicity Study of Human Papillomavirus (HPV16+) Immunotherapy VB10.16 in Women With High Grade Cervical Intraepithelial Neoplasia (HSIL; CIN 2/3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vaccibody AS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Theradex</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vaccibody AS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an exploratory, open, prospective multi-centre study of VB10.16 immunotherapy in&#xD;
      patients with high grade HPV16+ Cervical Intraepithelial Neoplasia (HSIL; CIN2/3). This study&#xD;
      will recruit approximately 27-40 female patients with high grade cervical intraepithelial&#xD;
      neoplasia (HSIL, CIN 2/3) at multiple sites in Europe.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be divided into two phases, a dosing and expansion phase.&#xD;
&#xD;
      During the dosing phase the safety, tolerability and immunogenicity of 2 different&#xD;
      vaccination schedules of 3 mg VB10.16 immunotherapy will be established in a minimum of 12&#xD;
      patients with histology confirmed CIN 2.&#xD;
&#xD;
      During the expansion phase the safety, tolerability and immunogenicity of the selected&#xD;
      vaccination schedule will be evaluated in approximately 15 to 20 patients with histology&#xD;
      confirmed HPV16+ CIN 2/3.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">January 31, 2019</completion_date>
  <primary_completion_date type="Actual">January 31, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety/tolerability</measure>
    <time_frame>6 months (extended follow up for additional 6 months)</time_frame>
    <description>- The percentage of patients with adverse events (AEs), including any dose-limiting toxicities (DLT), laboratory assessments and physical findings.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>6 months</time_frame>
    <description>The percentage of patients with E6/E7 specific cellular immune response in the blood.&#xD;
The percentage of patients with cellular immune response in the target lesions.&#xD;
The percentage of patients with humoral response against the E6/E7 viral antigen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary assessment of efficacy</measure>
    <time_frame>6 months (extended follow up for additional 6 months)</time_frame>
    <description>The percentage of patients with HPV16+ clearance.&#xD;
The percentage of patients with lesion regression</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>High Grade Cervical Intraepithelial Neoplasia</condition>
  <arm_group>
    <arm_group_label>Cohort 1: 3mg VB10.16 Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VB10.16 Immunotherapy (DNA vaccine): Biological/Vaccine Vaccination time points: Week 0, Week 3, Week 6, 3mgs per vaccination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: 3mg VB10.16 Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VB10.16 Immunotherapy (DNA vaccine): Biological/Vaccine Vaccination time points: Week 0, Week 4, Week 8, 3mgs per vaccination</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VB10.16 Immunotherapy (DNA vaccine)</intervention_name>
    <description>Patients will receive 3 vaccinations of 3 mg VB10.16 at the pre-specified time points. VB10.16 will be administered intramuscularly in the area over the lateral deltoid muscle.</description>
    <arm_group_label>Cohort 1: 3mg VB10.16 Vaccine</arm_group_label>
    <arm_group_label>Cohort 2: 3mg VB10.16 Vaccine</arm_group_label>
    <other_name>Biological/Vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (abbreviated):&#xD;
&#xD;
          1. Women ≥18 years&#xD;
&#xD;
          2. Women with ectocervical HPV16+ associated High Grade Cervical Intraepithelial&#xD;
             Neoplasia (HSIL) as verified by local pathology:&#xD;
&#xD;
             (Dosing Phase: Women with histologically confirmed HPV16+ associated CIN 2; Expansion&#xD;
             Phase: Women with histologically confirmed HPV16+ associated CIN 2/3)&#xD;
&#xD;
          3. Satisfactory colposcopic examination.&#xD;
&#xD;
        Exclusion Criteria (abbreviated):&#xD;
&#xD;
          1. More than 2 cervical quadrants of CIN 3 as visualised by colposcopy.&#xD;
&#xD;
          2. Atypical glandular cells (AGC) or adenocarcinoma in situ (AIS) on cytology, malignant&#xD;
             cells on cytology or histology or other suspicion of either micro-invasive or invasive&#xD;
             disease.&#xD;
&#xD;
          3. Current severe pelvic inflammatory disease, severe cervicitis, or other severe&#xD;
             gynaecological infection as per colposcopy and clinical examination.&#xD;
&#xD;
          4. Positive serological test for hepatitis C virus or hepatitis B virus surface antigen&#xD;
             (HBsAg) or human immunodeficiency virus (HIV).&#xD;
&#xD;
          5. Administration of any blood product within 3 months of enrolment.&#xD;
&#xD;
          6. Concomitant or prior malignant disease.&#xD;
&#xD;
          7. Clinically significant autoimmune disease.&#xD;
&#xD;
          8. Known allergy to Kanamycin or other aminoglycosides&#xD;
&#xD;
          9. Known immunodeficiency and or immunosuppression.&#xD;
&#xD;
         10. History of toxic shock syndrome.&#xD;
&#xD;
         11. Evidence or history of clinically significant cardiac disease&#xD;
&#xD;
         12. Active infection requiring parenteral antibiotics.&#xD;
&#xD;
         13. Tattoos, scars, or active lesions/rashes within 2 cm of the site of vaccination or any&#xD;
             implantable leads.&#xD;
&#xD;
         14. Immunosuppression&#xD;
&#xD;
         15. Major surgery within 3 months of trial entry.&#xD;
&#xD;
         16. Current or recent (within 30 days of first study treatment) participation in a&#xD;
             clinical trial.&#xD;
&#xD;
         17. Previous vaccination (either therapeutic and/or prophylactic) against HPV.&#xD;
&#xD;
         18. Administration of any live vaccine within 90 days of trial entry.&#xD;
&#xD;
         19. Concomitant anticancer therapies.&#xD;
&#xD;
         20. Inadequate bone marrow function&#xD;
&#xD;
         21. Inadequate liver function&#xD;
&#xD;
         22. Clinical significant electrolyte abnormalities&#xD;
&#xD;
         23. Women of childbearing age not willing to use an effective form of contraception&#xD;
&#xD;
         24. Pregnancy or intention to become pregnant&#xD;
&#xD;
         25. Nursing women&#xD;
&#xD;
         26. Evidence of any other medical condition that may interfere with study participation,&#xD;
             patient compliance or place the patient at high risk from treatment-related&#xD;
             complications&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irene Skjørestad, MSc</last_name>
    <role>Study Director</role>
    <affiliation>Vaccibody AS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <state>Lower Saxony</state>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical School Hanover</name>
      <address>
        <city>Hannover</city>
        <state>Lower Saxony</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Wolfsburg</name>
      <address>
        <city>Wolfsburg</city>
        <state>Lower Saxony</state>
        <zip>38440</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IZD Institut für Zytologie und Dysplasie</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>August 19, 2015</study_first_submitted>
  <study_first_submitted_qc>August 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2015</study_first_posted>
  <last_update_submitted>March 1, 2019</last_update_submitted>
  <last_update_submitted_qc>March 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HSIL</keyword>
  <keyword>CIN 2/3</keyword>
  <keyword>Therapeutic DNA vaccine</keyword>
  <keyword>Human Papillomavirus</keyword>
  <keyword>Immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

